Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mario Chiong is active.

Publication


Featured researches published by Mario Chiong.


Journal of Cardiac Failure | 2014

Effects of trimetazidine in nonischemic heart failure: a randomized study.

José Luis Winter; Pablo Castro; Juan Carlos Quintana; Rodrigo Altamirano; Andrés Enríquez; Hugo Verdejo; Jorge Jalil; Rosemarie Mellado; Roberto Concepción; Pablo Sepúlveda; Víctor Rossel; Luis Sepulveda; Mario Chiong; Lorena García; Sergio Lavandero

OBJECTIVES Heart failure (HF) is associated with changes in myocardial metabolism that lead to impairment of contractile function. Trimetazidine (TMZ) modulates cardiac energetic efficiency and improves outcomes in ischemic heart disease. We evaluated the effects of TMZ on left ventricular ejection fraction (LVEF), cardiac metabolism, exercise capacity, O2 uptake, and quality of life in patients with nonischemic HF. METHODS AND RESULTS Sixty patients with stable nonischemic HF under optimal medical therapy were included in this randomized double-blind study. Patients were randomized to TMZ (35 mg orally twice a day) or placebo for 6 months. LVEF, 6-minute walk test (6MWT), maximum O2 uptake in cardiopulmonary exercise test, different markers of metabolism, oxidative stress, and endothelial function, and quality of life were assessed at baseline and after TMZ treatment. Left ventricular peak glucose uptake was evaluated with the use of the maximum standardized uptake value (SUV) by 18-fluorodeoxyglucose positron emission tomography ((18)FDG-PET). Etiology was idiopathic in 85% and hypertensive in 15%. Both groups were similar in age, functional class, LVEF, and levels of N-terminal pro-B-type natriuretic peptide at baseline. After 6 months of TMZ treatment, no changes were observed in LVEF (31 ± 10% vs 34 ± 8%; P = .8), 6MWT (443 ± 25 m vs 506 ± 79 m; P = .03), maximum O2 uptake (19.1 ± 5.0 mL kg(-1) min(-1) vs 23.0 ± 7.2 mL kg(-1) min(-1); P = .11), functional class (percentages of patients in functional classes I/II/III/IV 10/3753/0 vs 7/40/50/3; P = .14), or quality of life (32 ± 26 points vs 24 ± 18 points; P = .25) in TMZ versus placebo, respectively. In the subgroup of patients evaluated with (18)FDG-PET, no significant differences were observed in SUV between both groups (7.0 ± 3.6 vs 8.2 ± 3.4 respectively; P = .47). CONCLUSIONS In patients with nonischemic HF, the addition of TMZ to optimal medical treatment does not result in significant changes of LVEF, exercise capacity, O2 uptake, or quality of life.


Revista Espanola De Cardiologia | 2004

Effects of Carvedilol on Functional Capacity, Left Ventricular Function, Catecholamines, and Oxidative Stress in Patients With Chronic Heart Failure

Pablo Castro; Osvaldo Pérez; Douglas Greig; Guillermo Díaz-Araya; Francisco Moraga; Mario Chiong; Rodrigo Troncoso; Ivonne Padilla; José Luis Vukasovic; Ramón Corbalán; Sergio Lavandero

INTRODUCTION AND OBJECTIVE Carvedilol is an antioxidant and adrenergic antagonist with demonstrated benefits in terms of mortality from heart failure (HF). The aim of the present study was to evaluate clinical parameters, left ventricular function, oxidative stress levels and neurohumoral status at baseline and after 6 months of treatment with carvedilol in patients with chronic HF. PATIENTS AND METHOD Thirty patients with chronic HF that was stable without beta blocker treatment were included. Functional class was II or III, and left ventricular ejection fraction (LVEF) was < 40%. Mahler score, distance walked in 6 min, peak oxygen consumption, LVEF, plasma catecholamine (norepinephrine) concentration and oxidative stress parameters were evaluated at baseline and after 6 months of treatment with carvedilol. RESULTS Mean age was 59 (2) years, and 23 patients were men. After 6 months of treatment there were clinical improvements as measured by the Mahler score (from 6.8 to 11.0 points; P=.001) and the 6-min walk distance (from 499 [18] to 534 [17] m; P =.032), but no changes in peak oxygen consumption. The LVEF increased from 24 (1) to 31 (2)% (P=.003). In patients with chronic HF, plasma malondialdehyde concentration was significantly lower after 6 months (decrease from 2.4 [0.2] to 1.1 [0.2] micromol/l; P<.001). No significant changes were observed in plasma catecholamine levels or antioxidant enzyme activities. CONCLUSIONS In patients with chronic HF, carvedilol treatment for 6 months was associated with clinical improvements, increased left ventricular function and decreased plasma concentrations of malondialdehyde, with no changes in plasma catecholamine levels.


European Journal of Sport Science | 2018

Potential adverse cardiac remodelling in highly trained athletes: still unknown clinical significance

Luigi Gabrielli; Marta Sitges; Mario Chiong; Jorge Jalil; María Paz Ocaranza; Silvana Llevaneras; Sebastián Herrera; Rodrigo Fernández; Rodrigo Saavedra; Fernando Yañez; Luis Vergara; Alexis Diaz; Sergio Lavandero; Pablo Castro

Abstract Moderate endurance exercise has long been considered an essential element to maintain cardiovascular health, and sedentary behaviour in the general population has been related to a significant increase in all-causes of mortality, cardiovascular disease mortality and cardiovascular disease incidence. However, a growing group of people performs an intense exercise that leads to multiple heart adaptive changes that are collectively called “athlete’s heart”. In this review, we discussed the evidence of cardiac remodelling process secondary to repetitive and strenuous exercise in some predisposed athletes that produces intense and probably deleterious changes in cardiac morphology and function with no clear clinical significance in long-term follow-up. Moreover, we also discussed the individual biological response to exercise assessed by myocardial damage, inflammation, oxidative stress, fibrosis and ventricular hypertrophy biomarkers showing different intensities with equivalent exertion.


Archive | 1997

Procedure for detoxification of shellfish, contaminated with paralytic shellfish toxins

Jenny M. Blamey; Max Rutman; Juan Pablo Hinrichsen; María Paz Ocaranza; Claudia López; Nestor Lagos; Mario Chiong


Revista Espanola De Cardiologia | 2004

Efectos del carvedilol en la capacidad funcional, función ventricular izquierda, catecolaminas y estrés oxidativo en pacientes con insuficiencia cardíaca crónica

Pablo Castro; Osvaldo Pérez; Douglas Greig; Guillermo Díaz-Araya; Francisco Moraga; Mario Chiong; Rodrigo Troncoso; Ivonne Padilla; José Luis Vukasovic; Ramón Corbalán; Sergio Lavandero


Revista chilena de cardiología | 2018

Entrenamiento físico de alta intensidad en maratonistas produce mayor remodelado cardíaco y reduce respuesta de estrés oxidativo

Julián Vega; Felipe Contreras-Briceño; Rodrigo Saavedra; Rodrigo Fernández; Sebastián Herrera; Manuel Salinas; Paz Godoy; María Paz Ocaranza; Jorge Jalil; Sergio Lavandero; Mario Chiong; Pablo Castro; Roberto Urzúa; Mario Muñoz; Ricardo Zalaquett; Luigi Gabrielli


MOJ Gerontology & Geriatrics | 2017

Red cell distribution width as biomarker in older adults: a brief review

Hernán Alcaíno; Mario Chiong; David Reyes; Humberto Toledo


Archive | 2014

Clinical Trial Effects of Trimetazidine in Nonischemic Heart Failure: A Randomized Study

José Luis Winter; Pablo Castro; Juan Carlos Quintana; Rodrigo Altamirano; Andrés Enríquez; Hugo Verdejo; Jorge Jalil; Rosemarie Mellado; Roberto Concepci On; Pablo Sep Ulveda; Víctor Rossel; Luis Sep Ulveda; Mario Chiong; Lorena García; Sergio Lavandero


Archive | 2013

ENDOCYTIC PATHWAY OF EXOGENOUS IRON-LOADED FERRITIN IN INTESTINAL 1

Elmer Antileo; Carolina Garri; Victoria Tapia; Juan Pablo Muñoz; Mario Chiong; Francisco; Sergio Lavandero; Juan Fernández; Marco T. Núñez; Facultad Ciencias Químicas


Archive | 2013

intestinal epithelial (Caco-2) cells Endocytic pathway of exogenous iron-loaded ferritin in

Francisco Nualart; Sergio Lavandero; Juan Fernández; Marco T. Núñez; Elmer Antileo; Carolina Garri; Victoria Tapia; Juan Pablo Muñoz; Mario Chiong

Collaboration


Dive into the Mario Chiong's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pablo Castro

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jorge Jalil

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

María Paz Ocaranza

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hugo Verdejo

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar

Ivonne Padilla

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar

José Luis Winter

Pontifical Catholic University of Chile

View shared research outputs
Researchain Logo
Decentralizing Knowledge